22.418 articles found

Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications.

Eggert K, Schrader C, Hahn M, Stamelou M, Rüssmann A, Dengler R, Oertel W, Odin P.

Clin Neuropharmacol · 2008-05-01

DOI: 10.1097/wnf.0b013e31814b113ePMID: 18520982

The neuroscientist's melting pot: immunology, cell transplantation and other delivery systems, and enlightenment of disease etiology and treatment.

Eve DJ, Sanberg PR.

Neurotox Res · 2008-05-01

DOI: 10.1007/bf03033511PMID: 18522907

Essential tremor: symptoms and treatment.

Wick JY, Zanni GR.

Consult Pharm · 2008-05-01

DOI: 10.4140/tcp.n.2008.364PMID: 18540790

Rotigotine transdermal system for the treatment of Parkinson's disease.

Pham DQ, Nogid A.

Clin Ther · 2008-05-01

DOI: 10.1016/j.clinthera.2008.05.007PMID: 18555929

Effect of therapy on motor cortical excitability in Parkinson's disease.

Soysal A, Sobe I, Atay T, Sen A, Arpaci B.

Can J Neurol Sci · 2008-05-01

DOI: 10.1017/s0317167100008581PMID: 18574929

[Therapy of Parkinson's disease 2008].

Deuschl G.

MMW Fortschr Med · 2008-05-01

PMID: 18678055

Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders.

Neff F, Wei X, Nölker C, Bacher M, Du Y, Dodel R.

Autoimmun Rev · 2008-05-01

DOI: 10.1016/j.autrev.2008.04.010PMID: 18558370

COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES

ESPOSITO LUKE, CUMMINGS JOEL, HUDSON F. MICHAEL, SNOW ALAN.

· 2008-04-30

Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases.

Vegeto E, Benedusi V, Maggi A.

Front Neuroendocrinol · 2008-04-29

DOI: 10.1016/j.yfrne.2008.04.001PMID: 18522863

Adenosine A(2A) receptors in Parkinson's disease treatment.

Cieślak M, Komoszyński M, Wojtczak A.

Purinergic Signal · 2008-04-26

DOI: 10.1007/s11302-008-9100-8PMID: 18438720

USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE

DELAY-GOYET PHILIPPE, DELGORGE CLAIRE, MENET CHRISTINE, POUGHON GILLES, RAVINET-TRILLOU CHRISTINE.

· 2008-04-16

USE OF 4-CYCLOPROPYLMETHOXY-N-(3,5-DICHLORO-1-OXIDOPYRIDIN-4-YL)-5-(METHOXY)PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF MOTOR DISORDERS RELATED TO PARKINSON'S DISEASE

DELAY-GOYET PHILIPPE, DELGORGE CLAIRE, MENET CHRISTINE, POUGHON GILLES, RAVINET-TRILLOU CHRISTINE.

· 2008-04-16